Clinical Evaluation of Tavocept to Decrease Diuresis Time and Volume in Dogs with Bladder Cancer Receiving Cisplatin

BACKGROUND: Transitional cell carcinoma is the most common bladder cancer of dogs. Cisplatin combined with piroxicam provides superior response rates, but unacceptable rates of nephrotoxicity. Tavocept is a chemoprotectant that has mitigated cisplatin toxicity and decreased the required infusion/diu...

Descripción completa

Detalles Bibliográficos
Autores principales: Henry, C.J., Flesner, B.K., Bechtel, S.A., Bryan, J.N., Tate, D.J., Selting, K.A., Lattimer, J.C., Bryan, M.E., Grubb, L., Hausheer, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
SMALL ANIMAL
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787204/
https://www.ncbi.nlm.nih.gov/pubmed/29080252
http://dx.doi.org/10.1111/jvim.14848

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787204/
https://www.ncbi.nlm.nih.gov/pubmed/29080252
http://dx.doi.org/10.1111/jvim.14848

Ejemplares similares